NasdaqGM:VCELBiotechs
Is Vericel’s Rebound After FDA Updates a Sign the Market Sees More Value?
If you have been eyeing Vericel lately and wondering whether it’s time to buy, hold, or move on, you are definitely not alone. Over just the past month, the stock has surged nearly 14%, a dramatic rebound that stands in stark contrast to its year-to-date decline of 34.6%. That kind of movement can make anyone question what is really going on beneath the surface.
For context, Vericel recently grabbed headlines with FDA updates on its cell therapy pipeline, sparking renewed enthusiasm among...